CD44 and acute myeloid leukemia: In acute myeloid leukemia, the administration of a monoclonal antibody against CD44 markedly reduced the repopulation of leukemic stem cells in vivo; however, this effect was due to the inhibition of proper homing of leukemic stem cells to microenvironmental niches.